PeptiDream Inc. (TYO:4587)
Japan · Delayed Price · Currency is JPY | Market Cap | 152.80B -44.9% |
| Revenue (ttm) | 18.52B -60.3% |
| Net Income | -3.75B |
| EPS | -28.99 |
| Shares Out | 129.21M |
| PE Ratio | n/a |
| Forward PE | 11.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 936,600 |
| Average Volume | 1,018,840 |
| Open | 1,182.00 |
| Previous Close | 1,206.00 |
| Day's Range | 1,171.00 - 1,192.00 |
| 52-Week Range | 1,131.50 - 2,029.00 |
| Beta | 0.18 |
| RSI | 39.87 |
| Earnings Date | May 12, 2026 |
About PeptiDream
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery c... [Read more]
Financial Performance
Financial StatementsNews
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational clin...
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
KAWASAKI, Japan--(BUSINESS WIRE)-- #IL17--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.